139 related articles for article (PubMed ID: 7504134)
1. Effects of doxazosin and hydrochlorothiazide on lipid levels in Korean patients with essential hypertension.
Jones DW; Sands CD
J Cardiovasc Pharmacol; 1993 Sep; 22(3):431-7. PubMed ID: 7504134
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension.
Trost BN; Weidmann P; Riesen W; Claessens J; Streulens Y; Nelemans F
Am J Cardiol; 1987 May; 59(14):99G-104G. PubMed ID: 2884861
[TBL] [Abstract][Full Text] [Related]
3. Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension.
Levy D; Walmsley P; Levenstein M
Am Heart J; 1996 May; 131(5):966-73. PubMed ID: 8615318
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group.
Grimm RH; Flack JM; Grandits GA; Elmer PJ; Neaton JD; Cutler JA; Lewis C; McDonald R; Schoenberger J; Stamler J
JAMA; 1996 May 22-29; 275(20):1549-56. PubMed ID: 8622245
[TBL] [Abstract][Full Text] [Related]
5. Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trail comparing doxazosin and hydrochlorothiazide.
Grimm RH; Flack JM; Schoenberger JA; Gonzalez NM; Liebson PR
Am J Hypertens; 1996 May; 9(5):445-54. PubMed ID: 8735175
[TBL] [Abstract][Full Text] [Related]
6. Changes in lipid and lipoprotein values during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
Ahaneku JE; Taylor GO; Agbedana EO; Walker O; Salako LA
J Pak Med Assoc; 1994 Jul; 44(7):166-9. PubMed ID: 7933456
[TBL] [Abstract][Full Text] [Related]
7. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
Pool JL
Am J Cardiol; 1987 May; 59(14):46G-50G. PubMed ID: 2884853
[TBL] [Abstract][Full Text] [Related]
8. Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group.
Carruthers G; Dessain P; Fodor G; Newman C; Palmer W; Sim D
Am J Cardiol; 1993 Mar; 71(7):575-81. PubMed ID: 8438744
[TBL] [Abstract][Full Text] [Related]
9. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension.
Derosa G; Cicero AF; Gaddi A; Mugellini A; Ciccarelli L; Fogari R
J Cardiovasc Pharmacol; 2005 Jun; 45(6):599-604. PubMed ID: 15897788
[TBL] [Abstract][Full Text] [Related]
10. The antihypertensive effects of doxazosin: a clinical overview.
Cox DA; Leader JP; Milson JA; Singleton W
Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):83S-90S. PubMed ID: 2939872
[TBL] [Abstract][Full Text] [Related]
11. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk.
Daae LN; Westlie L
Blood Press; 1998 Jan; 7(1):39-45. PubMed ID: 9551876
[TBL] [Abstract][Full Text] [Related]
12. Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study.
Rabkin SW; Huff MW; Newman C; Sim D; Carruthers SG
Hypertension; 1994 Aug; 24(2):241-8. PubMed ID: 8039850
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
14. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients.
Fogari R; Zoppi A; Malamani GD; Marasi G; Vanasia A; Villa G
Br J Clin Pharmacol; 1995 May; 39(5):471-6. PubMed ID: 7669481
[TBL] [Abstract][Full Text] [Related]
15. Long-term lipid profiles with isradipine and hydrochlorothiazide treatment in elderly hypertensive patients.
Stein GH; Matthews K; Bannatyne RE; Quay G; Lopez L; McCarley D
J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S90-2. PubMed ID: 1695313
[TBL] [Abstract][Full Text] [Related]
16. Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension.
Campo C; Segura J; Roldán C; Alcázar JM; Rodicio JL; Ruilope LM
Blood Press Suppl; 2003 Dec; 2():16-21. PubMed ID: 14761072
[TBL] [Abstract][Full Text] [Related]
17. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients.
Hirano T; Yoshino G; Kashiwazaki K; Adachi M
Am J Hypertens; 2001 Sep; 14(9 Pt 1):908-13. PubMed ID: 11587157
[TBL] [Abstract][Full Text] [Related]
18. Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins.
Lehtonen A; Himanen P; Saraste M; Niittymäki K; Marniemi J
Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):77S-81S. PubMed ID: 2939871
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
[TBL] [Abstract][Full Text] [Related]
20. The effects of thiazide diuretics upon plasma lipoproteins.
Johnson BF; Saunders R; Hickler R; Marwaha R; Johnson J
J Hypertens; 1986 Apr; 4(2):235-9. PubMed ID: 3519766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
